Descubra el nuevo Chem-Impex: donde la innovación comienza con un vínculo.

Catalog Number:
38371
CAS Number:
107753-78-6
Zafirlukast
Purity:
≥ 98 % (HPLC)
Synonym(s):
N- [3-[[2-Metoxi-4-[[[(2-metilfenil)sulfonil]amino]carbonil]fenil]metil]-1-metil- 1H -indol-5-il]carbamato de ciclopentilo, Éster ciclopentílico del ácido N- [3-[[2-metoxi-4-[[[(2-metilfenil)sulfonil]amino]carbonil]fenil]metil]-1-metil- 1H -indol-5-il]carbámico
Documents
$48.27 /100 mg
Tamaño
Request Bulk Quote
Información del producto

Conservar bajo gas inerte.

Número CAS
107753-78-6
Fórmula molecular
C31H33N3O6S
Peso molecular
575.68
Número MDL
MFCD00864775
Condiciones
Conservar entre 2 y 8 °C.
Información general
Número CAS
107753-78-6
Fórmula molecular
C31H33N3O6S
Peso molecular
575.68
Número MDL
MFCD00864775
Condiciones
Conservar entre 2 y 8 °C.
Propiedades
¡Pronto habrá más información sobre la propiedad!
-
Seguridad y normativas
Materiales peligrosos
-
Antibiótico
-
Regulado por la DEA
No
Advertencias
-
Aplicaciones

Zafirlukast is widely utilized in research focused on:

  • Asthma Management: This compound is primarily used as a leukotriene receptor antagonist, helping to reduce inflammation and bronchoconstriction in asthma patients, thereby improving their breathing and overall quality of life.
  • Allergy Treatment: It is effective in managing allergic rhinitis symptoms, providing relief from nasal congestion and other allergy-related issues, making it a valuable option for individuals suffering from seasonal allergies.
  • Clinical Research: Zafirlukast is often studied in clinical trials to evaluate its efficacy in combination therapies for respiratory diseases, offering insights into new treatment protocols and improving patient outcomes.
  • Pharmaceutical Development: The compound serves as a model for developing new drugs targeting similar pathways, aiding researchers in creating more effective treatments for chronic respiratory conditions.
  • Personalized Medicine: Its application in pharmacogenomics allows for tailored treatment plans based on individual patient responses, enhancing therapeutic effectiveness and minimizing side effects.

Citas